201 related articles for article (PubMed ID: 35648149)
1. Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.
Eide Kvitne K; Hole K; Krogstad V; Wollmann BM; Wegler C; Johnson LK; Hertel JK; Artursson P; Karlsson C; Andersson S; Andersson TB; Sandbu R; Hjelmesæth J; Skovlund E; Christensen H; Jansson-Löfmark R; Åsberg A; Molden E; Robertsen I
Eur J Clin Pharmacol; 2022 Aug; 78(8):1289-1299. PubMed ID: 35648149
[TBL] [Abstract][Full Text] [Related]
2. 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?
Gjestad C; Huynh DK; Haslemo T; Molden E
Br J Clin Pharmacol; 2016 Feb; 81(2):269-76. PubMed ID: 26574235
[TBL] [Abstract][Full Text] [Related]
3. Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers.
Gjestad C; Hole K; Haslemo T; Diczfalusy U; Molden E
AAPS J; 2019 Apr; 21(4):58. PubMed ID: 31020430
[TBL] [Abstract][Full Text] [Related]
4. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
Gjestad C; Haslemo T; Andreassen OA; Molden E
Br J Clin Pharmacol; 2017 Nov; 83(11):2398-2405. PubMed ID: 28585378
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
[TBL] [Abstract][Full Text] [Related]
6. Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.
Hole K; Heiberg PL; Gjestad C; Mehus LL; Rø Ø; Molden E
Pharmacol Res Perspect; 2018 Oct; 6(5):e00430. PubMed ID: 30214813
[TBL] [Abstract][Full Text] [Related]
7. Formation of CYP3A-specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β-hydroxycholesterol/cholesterol ratio.
Lee J; Fallon JK; Smith PC; Jackson KD
Clin Transl Sci; 2023 Feb; 16(2):279-291. PubMed ID: 36350327
[TBL] [Abstract][Full Text] [Related]
8. The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
Størset E; Hole K; Midtvedt K; Bergan S; Molden E; Åsberg A
Br J Clin Pharmacol; 2017 Jul; 83(7):1457-1465. PubMed ID: 28146606
[TBL] [Abstract][Full Text] [Related]
9. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.
Hole K; Gjestad C; Heitmann KM; Haslemo T; Molden E; Bremer S
Eur J Clin Pharmacol; 2017 Mar; 73(3):317-324. PubMed ID: 27975131
[TBL] [Abstract][Full Text] [Related]
11. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker.
Hole K; Wollmann BM; Nguyen C; Haslemo T; Molden E
Ther Drug Monit; 2018 Aug; 40(4):463-468. PubMed ID: 29649093
[TBL] [Abstract][Full Text] [Related]
13. Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
Vanhove T; Hasan M; Annaert P; Oswald S; Kuypers DRJ
Br J Clin Pharmacol; 2017 Nov; 83(11):2406-2415. PubMed ID: 28603840
[TBL] [Abstract][Full Text] [Related]
14. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
Diczfalusy U; Nylén H; Elander P; Bertilsson L
Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
[TBL] [Abstract][Full Text] [Related]
15. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
Penzak SR; Rojas-Fernandez C
J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
[TBL] [Abstract][Full Text] [Related]
16. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
[TBL] [Abstract][Full Text] [Related]
17. No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.
Mannheimer B; Wagner H; Östenson CG; Diczfalusy U
PLoS One; 2015; 10(4):e0121984. PubMed ID: 25835492
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
19. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
